Login / Signup

Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes.

Miodrag JanićMatej CankarJan ŠmidAlenka France ŠtiglicAleš JerinMišo ŠabovičAndrej JanezMojca Lunder
Published in: Journal of diabetes research (2022)
Empagliflozin-metformin combination has strong antioxidative and anti-inflammatory capacity, in adults with type 1 diabetes that is greater than that for the individual drugs. Its antioxidative activity at least partially explains the improvement in arterial function. Therefore, it appears that the combination provides the most powerful vascular protection.
Keyphrases
  • anti inflammatory